- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This document presents experiences of how community-based antiretroviral therapy (ART) delivery can improve both the level of access to treatment and the quality of health outcomes for people living with HIV. These experiences illustrate that community-based ART delivery is efficient, effective and high quality.
This landscape analysis surveys the current state of technologies for the treatment of hepatitis C virus (HCV), as well as market dynamics that affect the affordability and accessibility of HCV therapeutics. HCV treatment falls within the ambit of UNITAID’s mission because it is a major HIV coinfection and a leading cause of morbidity and mortality among people living with HIV. Strategic Objective 3 of the UNITAID Strategy 2013−2016 specifically refers to viral hepatitis, notably hepatitis B and C.
Recent estimates report that only 54% of people with HIV know their HIV status. In order to reach the UN 90–90–90 goals it is critical that HIV testing services be strategically expanded to diagnose as many people with HIV as early as possible.
This fact sheet includes data on HIV testing services reported by countries to the Global AIDS Response Progress Reporting (GARPR) (WHO, UNAIDS, UNICEF) as of July 2015.
Launched only a year ago, Fast-Track cities has rapidly taken root and grown. This is the first annual update on progress in implementing the Fast-Track cities approach and it supports one of the seven key commitments contained in the Paris Declaration. This report reflects on the actions taken by cities and by the four core partners— the city of Paris, UNAIDS, the United Nations Human Settlements Programme (UN-Habitat) and the International Association of Providers of AIDS Care (IAPAC)—towards ending the AIDS epidemic as a public health threat by 2030. Future reports will illustrate good practices and quantifiable evidence of progress that will inspire and inform Fast-Track cities and the many stakeholders helping to confront AIDS as a health and development challenge.
Keywords: treatment, urban, AIDS epidemic, response, 90-90-90
UNAIDS welcomes additional evidence released in May 2015 that early initiation of antiretroviral therapy has a positive effect on the health and well-being of people living with HIV. The United States National Institutes of Health-funded international randomized clinical trial START (Strategic Timing of Antiretroviral Treatment) has found compelling evidence that the benefits of starting antiretroviral therapy as soon as someone is diagnosed outweigh the risks of delaying until their CD4 count has fallen to 350 cells/mm3.
Developed by Southern African AIDS Trust, with the support of WHO and UNAIDS, the summary of the the WHO’s New Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection is now available.
Among many new recommendations is that antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Another is that the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches.
In support of the United Nation's Millennium Developtrieht Goal Number 6 to halt or reverse the incidence of Human Immuno-deficiency Virus (HIV)/Acqnired' Immune Deficiency Virus (AIDS) by 2015, PhilHealth through Board Resolution No. 1331, series of 2009 has approved the implementation of an outpatient HIV/AIDS treatment package. This benefit aims to increase the proportion of the population having·access to effective HIV/AIDS treatment and patient education measures.
Surveillance of transmitted HIV drug resistance (TDR) in individuals recently infected with HIV was performed following WHO-suggested methods. The prevalence of transmitted HIV drug resistance (TDR) in recently infected antiretroviral drug naïve individuals in PNG has not been fully characterised.
The global effort to scale-up HIV treatment in low- and middle-income countries continues to move closer towards achieving the goal of 15 million people receiving treatment by 2015. By the end of 2012, 9.7 million people in low- and middle-income countries were receiving antiretroviral therapy (ART), which represents an increase of 1.7 million from the previous year.
The goal of this report is to provide countries and suppliers with a sense of how the global market for antiretroviral (ARV) medicines in low- and middle-income countries is likely to evolve from 2013 to 2016. The report also aims to provide suppliers with a global forecast of the estimated demand for active pharmaceutical ingredients (APIs) so that they can manage their manufacturing capacity accordingly.
Evidence has emerged over the past few years on the effectiveness of antiretroviral-based prevention technologies to prevent (i) HIV transmission while decreasing morbidity and mortality in HIV-infected persons, and (ii) HIV acquisition in HIV-uninfected individuals through pre-exposure prophylaxis (PrEP). Only few of the planned studies on treatment as prevention (TasP) are conducted in Asia. TasP might be more feasible and effective in concentrated rather than in generalised epidemics, as resources for HIV testing and antiretroviral treatment could focus on confined and much smaller populations than in the generalised epidemics observed in sub-Saharan Africa. Several countries such as Cambodia, China, Thailand and Vietnam, are now paving the way to success. Similar challenges arise for both TasP and PrEP. However, the operational issues for PrEP are amplified by the need for frequent retesting and ensuring adherence. This paper describes challenges for the implementation of antiretroviral-based prevention and makes the case that TasP and PrEP implementation research in Asia is much needed to provide insights into the feasibility of these interventions in populations where firm evidence of 'real world' effectiveness is still lacking.
Keywords: Cambodia, China, pre-exposure prophylaxis, Thailand, treatment as prevention, Vietnam